Ixabepilone

Microtubule Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Ixabepilone is an ofp drug in the Microtubule Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2007. DrugCentral lists 2 molecular targets, including BCL2 and TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8. Recorded indications include Carcinoma of breast and Metastatic Breast Carcinoma.

• Approval status: ofp (first approved 2007 by the FDA).
• Drug class: Microtubule Inhibitor.
• Molecular targets: BCL2 and TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8 (2 listed in DrugCentral).
• Indications: Carcinoma of breast and Metastatic Breast Carcinoma.
• ATC code: L01DC04 (Other cytotoxic antibiotics).
• Molecular formula: C27H42N2O5S; molecular weight 506.70 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Carcinoma of breast
• Metastatic Breast Carcinoma

Contraindications (15)

• Acute infectious disease
• Anemia
• Breastfeeding (mother)
• Conduction disorder of the heart
• Diabetes mellitus
• Disease of liver
• Heart disease
• Hepatic failure
• Hyperbilirubinemia
• Liver function tests abnormal
• Myocardial ischemia
• Neutropenic disorder
• Peripheral nerve disease
• Pregnancy, function
• Thrombocytopenic disorder

Mechanism & targets

• Established pharmacologic class: Microtubule Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Apoptosis regulator Bcl-2	BCL2	unknown	Kd 6.47
Tubulin beta	TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2007-10-16	FDA	—	BRISTOL MYERS SQUIBB

ATC classification

ATC code	Therapeutic hierarchy
L01DC04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES › Other cytotoxic antibiotics

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: ERBB2, ESR1, ESR2, PGR

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Pseudocirrhosis	196.8
Neutrophil count decreased	126.7
White blood cell count decreased	93.4
Portal hypertension	87.6
Malignant neoplasm progression	80.6
Anaemia	76.5
Neutropenia	67.6
Dehydration	51.8
Disease progression	46.0
Febrile neutropenia	44.7
Platelet count decreased	42.8
Peripheral sensory neuropathy	38.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ixabepilone is on its molecule page.

• Molecular formula: C₂₇H₄₂N₂O₅S
• Molecular weight: 506.70 g/mol
• CAS number: 219989-84-1
• InChIKey: FABUFPQFXZVHFB-PVYNADRNSA-N
• PubChem CID: 6445540

C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=CSC(C)=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ixabepilone used for?

DrugCentral lists the following indications for Ixabepilone: Carcinoma of breast and Metastatic Breast Carcinoma.

How does Ixabepilone work?

Its molecular targets in DrugCentral include BCL2 and TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8 (inhibitor).

When was Ixabepilone first approved?

Ixabepilone was first approved by the FDA in 2007.

What drug class does Ixabepilone belong to?

Ixabepilone is in the Microtubule Inhibitor class.

What is the chemical formula of Ixabepilone?

Ixabepilone has the molecular formula C27H42N2O5S and a molecular weight of 506.70 g/mol.

Sources

• DrugCentral drug card 1517 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201752 — compound record and bioactivity
• PubChem CID 6445540 — chemical identifiers
• DrugBank DB04845 — drug record
• FDA UNII K27005NP0A — substance identity
• DailyMed: FDA labels for Ixabepilone — current prescribing information (label search)
• UniProt P10415 (BCL2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.